The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivityRebecca Newton, Donald Ogilvie, Neil Q. McDonald et al.|European Journal of Medicinal Chemistry|2016Cited by 40
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson, Donald Ogilvie, Gemma V. Hopkins et al.|F1000Research|2016Cited by 6
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson, Donald Ogilvie, Gemma V. Hopkins et al.|F1000Research|2016Cited by 6
Datasets: selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeAmanda J. Watson, Donald Ogilvie, Gemma V. Hopkins et al.|Unknown|2025Cited by 0
Abstract C39: First-in-class inhibitors of the putatively undruggable DNA repair target Poly(ADP-ribose) glycohydrolase (PARG)Bohdan Waszkowycz, Donald Ogilvie, Dominic I. James et al.|Molecular Cancer Therapeutics|2015Cited by 0